Rutgers University School of Law
Juris Doctor, 1999

Rutgers University

Ph.D., Microbiology and Molecular Genetics, 1992

N. Y. Medical College

M.S., Microbiology, 1985

Virginia Wesleyan University

B.A., Biology, 1982

Activities & Affiliations

• AIPLA, Member

• PIPLA, Member

• LES, Member

Bar Admissions

• Pennsylvania, New Jersey

Kathleen D. Rigaut, PhD

Partner | 215-540-9212

Dr. Rigaut received a B.A. in Biology from Virginia Wesleyan College in 1982, an M.S. in Microbiology from N.Y. Medical College in 1985 and a Ph.D. in Microbiology and Molecular Genetics from Rutgers University in 1992. Dr. Rigaut was admitted to practice before the USPTO in 1998 and received a J.D. degree from Rutgers University in Camden in 1999. Kate was admitted to practice law in NJ and PA in 2000 and joined the firm as a partner in 2018. 

Kate has extensive laboratory experience in the fields of virology, immunology, and molecular biology. As a Staff Fellow at the National Institutes of Health, Kate was involved in the development of novel immunotoxins targeting the T Cell Receptor.

Publications co-authored by Kate include “Anti-CD3/CD4-CRM9: A Novel Bifunctional Immunotoxin Targeting CD3+CD4+ T Cells,” Tumor Targeting 2:76-84; “Selective Killing of T Cells by Immunotoxins Directed at Distinct Regions of the T Cell Receptor,” Eur. J. Immunol. 25:2077-2082; “Inhibition of VSV Infection by Staurosporine,” Virology 194:433-440; “Intracellular Distribution of Input Vesicular Stomatitis Virus Proteins after Uncoating,” J. Virology 65:2622-2628. Dr. Rigaut contributed a chapter on the clinical use of monoclonal antibodies for a book entitled “Biopharmaceutical Drug Design and Development” published by Humana Press in 1999. Kate has also contributed a book chapter to Research administration and Management Elliott C. Kulakowski, Lynne U. Chronister eds, Research Enterprise entitled “Applying for the United States Patent Protection” Kate has written a chapter on non-disclosure agreements which also appeared in Research Administration and Management.

Kate has extensive experience in patent prosecution, including preparation and filing of patent applications, amendments, and responses to PTO Official Actions on a variety of subjects including cancer genes, transgenic plants, RNA viruses, monoclonal antibodies, antisense technologies, and compositions involved in anti-inflammatory responses. She also prepared patentability and freedom to operate opinions.